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Summary
An enigmatic feature of many genetic diseases is that
mutations in widely expressed genes cause tissue-
specific illness. One example is DYT1 dystonia, a neu-
rodevelopmental disease caused by an in-frame dele-
tion (Dgag) in the gene encoding torsinA. Here we
show that neurons from both torsinA null (Tor1a2/2)
and homozygous disease mutant ‘‘knockin’’ mice
(Tor1aDgag/Dgag) contain severely abnormal nuclear
membranes, although non-neuronal cell types appear
normal. These membrane abnormalities develop in
postmigratory embryonic neurons and subsequently
worsen with further neuronal maturation, a finding
evocative of the developmental dependence of DYT1
dystonia. These observations demonstrate that neu-
rons have a unique requirement for nuclear envelope
localized torsinA function and suggest that loss of
this activity is a key molecular event in the pathogene-
sis of DYT1 dystonia.
Introduction
DYT1 dystonia is an autosomal-dominant disease in-
variably caused by a three base pair deletion in the
TOR1A gene. This mutation removes a codon (Dgag;
DE) that normally encodes a glutamic acid residue in
the C terminus of torsinA (Ozelius et al., 1997). Although
torsinA is broadly expressed (Ozelius et al., 1997), DYT1
dystonia manifests as abnormal, involuntary twisting
movements reflecting selective dysfunction of CNS mo-
tor circuits. In addition, the disease typically begins dur-
ing a discrete period of early childhood (Berardelli et al.,
1998; Bressman et al., 1994; Fahn et al., 1987), suggest-
ing that a developmental abnormality leads to the al-
tered CNS activity of DYT1 dystonia. These characteris-
tics suggest that understanding the pathogenesis of
DYT1 dystonia may provide unique insight into pro-
cesses involved in neuronal development and function.
TorsinA is a peripheral membrane protein that resides
in the lumen of the endoplasmic reticulum (Kustedjo
et al., 2000; Liu et al., 2003). TorsinA is a member of the
AAA+ (ATPase associated with different cellular activi-
ties) protein family; these proteins typically function as
oligomers and use the energy of ATP hydrolysis to disas-
semble protein complexes. AAA+ proteins participate in
a diverse range of biological functions, including mem-
*Correspondence: wtd3@columbia.edubrane trafficking, powering cellular motors, and protein
chaperone activities (Neuwald et al., 1999; Ogura and
Wilkinson, 2001; Patel and Latterich, 1998; Vale, 2000).
Although inclusion in the AAA+ protein family provides
little insight into the cellular role of torsinA, several ob-
servations indicate that the nuclear envelope lumen is a
site of torsinA activity (Gerace, 2004; Gonzalez-Alegre
and Paulson, 2004; Goodchild and Dauer, 2004; Naismith
et al., 2004). Consistent with this notion, torsinA interacts
with the luminal domain of the inner nuclear membrane
protein lamina-associated polypeptide 1 (LAP1) (Good-
child and Dauer, 2005). In addition, disease-associated
DE-torsinA accumulates abnormally in the nuclear enve-
lope (Gonzalez-Alegre and Paulson, 2004; Goodchild
and Dauer, 2004), suggesting that abnormal interaction
between DE-torsinA and a nuclear envelope binding
partner may contribute to disease pathogenesis.
Despite this progress in understanding the biology of
torsinA, there are no experiments demonstrating an
effect of wild-type or DE-torsinA on nuclear envelope
function, and existing animal models have provided
conflicting information as to whetherDE-torsinA is asso-
ciated with the nuclear envelope in vivo (Cao et al.,
2005; Goodchild and Dauer, 2004; Koh et al., 2004;
Sharma et al., 2005; Shashidharan et al., 2005). In addi-
tion, DE-torsinA abnormally accumulates in the nuclear
envelope of both neuronal and nonneuronal cells, calling
into question the relationship between nuclear envelope
function and disease pathogenesis. Furthermore, al-
though models of disease pathogenesis depend criti-
cally on understanding whether a pathogenic mutation
confers a gain or loss of function to the disease protein,
the effect of theDgag mutation on torsinA function is un-
clear. To address these limitations, we generated tor-
sinA null and Dgag knockin mice and have used these
animals to explore the normal cellular role of torsinA
and the effect of the DYT1 mutation on torsinA function.
Results
The DYT1 Dystonia Mutation Inhibits TorsinA
Function
We used gene targeting to generate torsinA null
(Tor1a2/2) (Figure 1B) and Dgag knockin (Tor1aDgag/Dgag)
mice (Figure 1C). The DYT1 knockin mice contain the
Dgag mutation in the endogenous mouse Tor1a gene
(Figures 1C and 1D). To prevent nonspecific effects
from the PGK-neomycin resistance selection cassette,
both lines of mice were crossed with transgenic Cre re-
combinase mice that excise the cassette from the germ
line (see the Supplemental Data available with this article
online). Tor1a+/2 and Tor1a+/Dgag heterozygous inter-
crosses generated all expected genotypes with normal
Mendelian frequency. However, while Tor1a+/2 and
Tor1a+/Dgag heterozygotes were indistinguishable from
their littermate controls, Tor1a2/2 and Tor1aDgag/Dgag
animals typically died within 48 hr of birth. Tor1a2/2
and Tor1aDgag/Dgag animals move, breath, and respond
to stimuli, but they typically fail to feed or vocalize.
Although torsinA is ubiquitously expressed at birth
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924Figure 1. TorsinA Null and Homozygous Disease Mutant Knockin Mice Both Exhibit Early Postnatal Lethality
(A–C) Structure of wild-type and mutated Tor1a alleles. (A) Depicts wild-type mouse allele, (B) depicts null allele, and (C) depicts disease mutant
(Dgag) knockin allele. Triangles indicate loxP sites following Cre recombinase-based excision of neomycin resistance cassette (see the Supple-
mental Data).
(D) Electrophoretogram of DNA sequence from a Dgag targeted ES clone. This sequence demonstrates the presence of the Dgag mutation in the
targeted clone.
(E) PCR genotyping of Tor1aDgag allele after Cre recombinase removal of the neomycin resistance cassette. DNA was amplified with primers
shown as arrows in (C). PCR products demonstrate successful Cre recombination based deletion of the neomycin resistance cassette with a sin-
gle 34 base pair loxP site remaining in the Tor1aDgag allele (shown in [C]).
(F) TorsinA is broadly expressed at birth. Protein lysates from new-born wild-type mouse tissues probed with anti-torsinA (upper panel) and anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPH; lower panel).
(G) Tor1a2/2 and Tor1aDgag/Dgag embryonic day (E) 18 embryos appear normally developed. Sections were stained with haematoxylin and eosin.(Figure 1F), Tor1a2/2 and Tor1aDgag/Dgag pups display
no obvious developmental abnormalities (Figure 1G).
The striking similarity between the Tor1a2/2 and
Tor1aDgag/Dgag animals suggested that Tor1aDgag may
be a loss-of-function allele. However, it remained possi-
ble that this comparison was confounded by genetic
background or that the Tor1aDgag allele might produce
more mechanistically complex effects than a simple
loss of function. Thus, we formally tested whether
Tor1aDgag was a loss-of-function allele by crossing it
onto the null background, generating Tor1aDgag/2 ani-
mals. Similar to Tor1a2/2 and Tor1aDgag/Dgag animals,
Tor1aDgag/2 mice appeared normally developed, but
failed to survive past 48 hr. Thus, our genetic analysis
suggests strongly that Tor1aDgag is a loss-of-function
allele.
To test whether the Dgag mutation might cause this
loss of function by altering the stability of torsinA pro-
tein, we next measured torsinA protein levels in the
Tor1a mutant mice. We found that steady-state levels
of torsinA decrease with Tor1aDgag gene dosage in all
tissues examined (Figure 2A), even though homozygous
Tor1aDgag/Dgag knockin mice have normal levels of tor-
sinA mRNA (Figure 2C). We subsequently assessed
whether torsinA protein levels are also reduced by the
Dgag mutation in the human disease. Similar to our re-
sults in mice, there is less torsinA in skin fibroblasts de-
rived from DYT1 patients (heterozygous for Dgag) com-
pared with controls (Figure 2D). These observationsindicate that Tor1aDgag animals accurately model some
of the molecular features of DYT1 dystonia and suggest
that loss of torsinA activity may contribute to the neuro-
logical symptoms of the disease.
CNS Structure Is Normal in Tor1a Mutant Mice
We next explored the effects of torsinA deficiency on the
developing CNS of Tor1a2/2 and Tor1aDgag/Dgag mice at
embryonic day 18 (E18), typically the final day of mouse
gestation. The brains of homozygous mutant animals
appear grossly normal (Figure 3A), exhibiting normal
neocortical layering (Figure 3B) and spinal cord devel-
opment (Figure 3C). In addition, normal levels of synap-
sin indicate that gross synaptic development in the
spinal cord, the most mature area of the CNS, is compa-
rable between Tor1a2/2 and Tor1aDgag/Dgag mice and
their wild-type littermates (Figure 3D). Because dopami-
nergic dysfunction is implicated in other forms of dysto-
nia (Bandmann and Wood, 2002), we examined the ni-
grostriatal dopaminergic system of E18 embryos. The
dopaminergic projections to the striatum appeared nor-
mal in both homozygous mutants (Figure 3E), further il-
lustrating normal circuitry development in these torsinA
mutant mice.
Neuronal Selective NuclearMembraneAbnormalities
in Tor1a Mutant Mice
Several lines of evidence indicate that torsinA functions
in the nuclear envelope lumen (Gerace, 2004; Goodchild
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et al., 2004). Furthermore, disease mutant torsinA abnor-
mally accumulates in the nuclear envelope in cells de-
rived from DYT1 dystonia patients (Goodchild and Da-
uer, 2004). These observations suggest that nuclear
envelope dysfunction may contribute to disease patho-
genesis in DYT1 dystonia. We therefore examined the
nuclear envelope in both lines of torsinA mutant mice.
This analysis revealed severe abnormalities of nuclear
envelope ultrastructure in the CNS of both Tor1a2/2
and Tor1aDgag/Dgag mice (Figures 4A and 4B), while the
main endoplasmic reticulum appears relatively unaf-
fected (Figure 4C). In both lines, the lumen of the neuro-
nal nuclear envelope contains large numbers of vesicles
(Figures 4A and 4B) that appear to derive from the inner
nuclear membrane (arrowhead in Figure 4E).
The similarly appearing membrane abnormalities of
Tor1a2/2 and Tor1aDgag/Dgag neurons again suggested
that the Dgag mutation is a loss-of-function allele,
prompting us to examine the nuclear envelope morphol-
ogy of Tor1a+/2, Tor1aDgag/2, and Tor1aDgag/+ animals.
Nuclear membrane abnormalities indistinguishable from
those in Tor1a2/2 and Tor1aDgag/Dgag animals were pres-
ent in the CNS of Tor1aDgag/2 mice. However, nuclear
membrane abnormalities were not present in Tor1a+/2
or Tor1aDgag/+ heterozygous animals (Figure 4F), sug-
gesting that there is sufficient torsinA function to main-
Figure 2. TorsinA Protein Levels Decrease with Tor1aDgag Gene
Dosage
(A) TorsinA protein levels in Tor1a mutant mice. There is a Tor1aDgag
allele-dependent decrease in steady-state torsinA levels. 1% SDS
extracted liver, brain, and mouse embryonic fibroblast (MEF) lysates
probed with rabbit anti-torsinA (torA; upper panels) and anti-GAPH
(lower panels) antibodies.
(B) Anti-torsinA antibody similarly recognizes wild-type and DE-
torsinA. Lysates from BHK21 cells expressing equal amounts of ei-
ther myc-tagged wild-type (WT; left lane) or DE mouse torsinA (right
lane) were probed with anti-myc (upper panel) and anti-torsinA anti-
bodies (lower panel). For further details see Goodchild and Dauer
(2005).
(C) TorsinA mRNA levels are unaffected by Tor1aDgag gene dosage.
Northern blot of RNA from two wild-type, Tor1a+/Dgag and Tor1aDgag/
Dgag embryos probed with mouse torsinA cDNA probe.
(D) TorsinA protein levels are reduced in DYT1 patients. 1% SDS ex-
tracted protein lysates from DYT1 patient fibroblasts probed with
anti-torsinA (upper panel) and anti-GAPH (lower panel).tain normal nuclear membrane morphology in these
animals. We exploited the presence of this cellular
phenotype to carefully test whether the effect of the
DYT1 mutation was mediated entirely through its effect
on protein levels (Figure 2) or whether it also affects
the activity of DE-torsinA protein. To explore this ques-
tion, we compared the steady-state levels of torsinA in
Tor1aDgag/Dgag brain with those of unaffected Tor1a+/2
animals. Although both of these mice have similar
steady-state levels of torsinA (Figures 4G and 2A), the
knockin mice exhibit the complete null phenotype, while
the heterozygous knockouts do not. Thus DE-torsinA
appears to be a hypoactive, perhaps inactive, form of
torsinA.
Interestingly, the nuclear membranes of blood-brain
barrier associated cells (both pericytes and endothelial
cells) appeared normal (Figure 5A), despite the presence
of abnormalities in adjacent neurons (asterisk in Fig-
ure 5A). We further assessed other CNS cell types and
found that both astrocytes and oligodendrocytes also
appeared normal (Figure 5B). We also failed to identify
nuclear envelope changes in any non-nervous system
tissue, despite examining connective, epithelial, and
muscle cell types (Figure 5C). Thus, the nuclear enve-
lope abnormalities appear to occur specifically in neu-
rons, similar to the tissue selectivity characteristic of
DYT1 dystonia.
To explore whether torsinA function might be particu-
larly important for certain neuronal populations, we per-
formed a broad assessment of nuclear envelope ultra-
structure in the CNS of E18 Tor1a2/2 and Tor1aDgag/Dgag
mice. Nuclear envelope abnormalities were observed
in multiple areas of the CNS, including neurons of
the spinal cord, pons, frontal cortex, and hippocampus.
Although the presence of luminal vesicles was wide-
spread, we observed that large ventral horn neurons
were particularly severely affected. Similar to these ul-
trastructural abnormalities, light microscopic analysis
revealed that the nuclear shape of Tor1a2/2 ventral
horn neurons is abnormally convoluted compared with
wild-type neurons (Figures 6A and 6B). However, the nu-
clear lamina remained intact in even these severely af-
fected cells. In addition, it appears that nuclear lamins
are not incorporated into the luminal vesicles because
the lamina thickness did not differ between wild-type
and Tor1a2/2 ventral horn neurons. Despite the occur-
rence of luminal vesicles in other spinal cord neurons,
we were unable to identify abnormalities in the nuclear
lamina anywhere other than the worst affected ventral
horn neurons (Figures 6C and 6D).
Nuclear Membrane Abnormalities Worsen
with Neuronal Maturation
Our broad assessment of nuclear envelope ultrastruc-
ture throughout the CNS also revealed that the severity
and number of affected cells clearly increases in a ros-
tral-caudal gradient, a pattern that mirrors the progres-
sion of CNS development. This apparent developmental
dependence prompted us to focus on events occurring
at the nuclear membrane during neuronal development.
Interestingly, we never observed vesicles in the nuclear
membranes of migrating cortical (E15) or spinal cord
(E12) neurons; the nuclear membranes of all migrating
cells were morphologically normal (Figure 7A and data
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(A–C) Tissue sections from E18 wild-type, Tor1a2/2, and Tor1aDgag/Dgag mice stained with haematoxylin and eosin. (A) Shows normally appearing
brain of Tor1a2/2 and Tor1aDgag/Dgag mice, (B) shows grossly normal cortical development, and (C) shows spinal cord of wild-type and Tor1a2/2
mice.
(D) SDS-PAGE of spinal cord lysates probed with anti-synapsin antibody.
(E) Dopamine transporter immunostaining of E18 wild-type, Tor1a2/2, and Tor1aDgag/Dgag striata illustrates the normal development of nigros-
triatal dopaminergic projections. CX, cortex; Str, striatum.not shown). While nuclear envelope vesicles were pres-
ent at these relatively early points in development (E12
ventral spinal cord), they were observed exclusively in
postmigratory cells (Figure 7B). The nucleus of migrat-
ing neurons is characteristically elongate and irregularly
shaped, but the nuclei of postmigratory neurons are
more rounded (Peters et al., 1991; Rakic et al., 1974)
(Figure 7C). This transformation of nuclear morphology
may reflect that different physical properties are re-
quired of migrating nuclei compared to the nuclei of ma-
ture postmigratory cells.
These data suggested that torsinA or its interacting
proteins might participate in the developmental trans-
formation of nuclear shape. To begin to explore this no-
tion, we examined the expression of torsinA and the tor-
sinA-interacting proteins LAP1 and LULL1 during spinal
cord development and maturation (Figure 7D). This anal-
ysis revealed that the expression of the largest LAP1 iso-
form, LAP1A, is upregulated at approximately the same
time that nuclear envelope vesicles begin to form (Fig-
ure 7D). However, neither LAP1 nor LULL1 expression
is altered in Tor1a2/2 spinal cord (Figure 7E), despite
the occurrence of nuclear envelope abnormalities in
this tissue.
We next examined the spinal cord of Tor1a2/2 E15
and E18 embryos to assess the relationship of nuclearenvelope abnormalities to postmigratory neuronal mat-
uration. Ventral regions of the spinal cord develop sev-
eral days prior to dorsal areas (Altman and Bayer,
2001). Similar to this developmental gradient, we ob-
served that at both ages there was a greater percentage
of cells with nuclear envelope abnormalities in ventral
compared to dorsal spinal cord (Figures 6 and 8A–8H).
Furthermore, the severity of membrane abnormalities
(number of vesicles/cell) worsened between E15 and
E18 in both dorsal and ventral regions. The progressive
increase in vesicle number suggests that the nuclear en-
velope retains and accumulates luminal vesicles over
time. Consequently, it appears that nuclear membrane
abnormalities develop following migration and worsen
concurrent with subsequent events of neuronal matura-
tion, including the transformation of nuclear shape.
Discussion
These data provide novel insight into the molecular
mechanism of DYT1 dystonia, demonstrating that the
DYT1 Dgag mutation acts through at least two indepen-
dent mechanisms to impair torsinA function. Our data
also demonstrate a unique requirement for torsinA func-
tion in neural tissue, the only tissue affected in the dis-
ease. Taken together, these findings suggest that loss
Neuronal Nuclear Membrane Disruption in Tor1a Mice
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(A) Neurons in both Tor1a2/2 and Tor1aDgag/Dgag E18 spinal cord contain similar appearing nuclear membrane abnormalities. Note that the af-
fected nuclei have normally appearing chromatin and do not appear to be undergoing apoptosis.
(B) Panels show enlargement of nuclear envelope shown by solid boxed areas in (A). Scale bars, 1 mm. N, nucleus; Cy, cytosol.
(C) Panels show enlargement of endoplasmic reticulum shown in dashed boxed areas in (A). Scale bars, 1 mm. NE, nuclear envelope; M, mito-
chondria; *, endoplasmic reticulum.
(D) Nuclear membrane abnormalities in the cortex of E18 Tor1a2/2 and Tor1aDgag/Dgag animals. Scale bars, 1 mm.
(E) Detail of ultrastructure from Tor1a2/2 and Tor1aDgag/Dgag spinal cord neurons shows vesicles in the nuclear envelope lumen (left; arrowhead
points to a vesicle budding from the inner nuclear membrane) and outer nuclear membrane envelopment (center). Scale bars, 1 mm.
(F) Nuclear membrane abnormalities are present in the spinal cord of E18 Tor1aDgag/2 but not Tor1aDgag/+ and Tor1a+/2 animals. Scale bars, 1 mm.
(G) Similar steady-state levels of torsinA in the brains of Tor1a+/2 and Tor1aDgag/Dgag mice. Lysates extracted with 1% SDS from individual E18
Tor1a mutant mice were probed with anti-torsinA and b-actin antibodies.of torsinA function within the neuronal nuclear envelope
may contribute to the pathogenesis of DYT1 dystonia.
The strikingly similar phenotypes of Tor1a2/2,
Tor1aDgag/2, and Tor1aDgag/Dgag animals demonstrates
that Tor1aDgag is a loss-of-function allele. One mecha-
nism by which the mutation causes loss of function is
to reduce the steady-state levels of torsinA. This conclu-
sion is supported by data showing a Tor1aDgag-related
gene dosage effect on torsinA levels in mice and de-
creased torsinA protein in skin fibroblasts derived fromDYT1 patients. This effect on torsinA levels appears
to be mediated entirely at the protein level, as
Tor1aDgag/Dgag mice have normal levels of torsinA mRNA.
We have previously shown that torsinA is abnormally lo-
cated in the nuclear envelope of fibroblasts derived from
DYT1 patients (Goodchild and Dauer, 2004), suggesting
that DE-torsinA protein remains in these cells. However,
it is unclear whether lower torsinA levels reflect a selec-
tive decrease of DE-torsinA or whether the presence of
DE-torsinA leads to a reduction of both wild-type and
Neuron
928Figure 5. Nuclear Envelope Abnormalities Are Absent from Nonneuronal Cell Types
(A) Blood-brain barrier of Tor1a2/2 spinal cord. Normal nuclear membranes of endothelial cells (end) and pericytes (peri). Vesicles are present in
the nuclear envelope of an adjacent neuron (nrn; marked with asterisk). Scale bar, 1 mm.
(B) Tor1a2/2 neuroglial lack nuclear envelope vesicles. Images show a cultured forebrain astrocyte and an oligodendrocyte from spinal cord
white matter. Scale bars, 500 nm.
(C) Tor1a2/2 connective, epithelial, and muscle cell types lack nuclear envelope vesicles. Also note the normal appearance of rough endoplasmic
reticulum (rER) in a Tor1a2/2 hepatocyte. Scale bars, 500 nm.DE-torsinA. Unfortunately, currently available antisera
are unable to distinguish between the single amino
acid difference of wild-type and mutant protein, pre-
cluding further study of this issue at this time.
Independent from its effect on torsinA levels, our data
also demonstrate that the DYT1Dgag mutation results in
an intrinsically hypoactive, potentially inactive, form of
torsinA. Central to this conclusion is the comparison be-
tween the Tor1a+/2 and Tor1aDgag/Dgag animals. While
torsinA levels are similar in the nervous system of
Tor1a+/2 and Tor1aDgag/Dgag mice, only Tor1aDgag/Dgag
mice display the characteristics of torsinA loss, namely
perinatal lethality and neuronal nuclear membrane ab-
normalities. Thus DE-torsinA is less active than the
wild-type protein. In fact, DE-torsinA in Tor1aDgag/Dgag
animals is unable to ameliorate any effect associated
with the complete absence of torsinA, indicating that it
could be inactive.
Several lines of evidence from in vitro studies of tor-
sinA suggest that a third mechanism may also reduce
torsinA activity in the heterozygous state of DYT1 dysto-
nia. AAA+ proteins typically operate as oligomers (Neu-
wald et al., 1999; Ogura and Wilkinson, 2001; Patel and
Latterich, 1998; Vale, 2000), and it has been shown that
wild-type and DE-torsinA can coassemble into hetero-
oligomers. Specifically, wild-type and DE-torsinA coim-
munoprecipitate (Torres et al., 2004), and the presence
of DE-torsinA causes wild-type protein to relocate to
the nuclear envelope (Goodchild and Dauer, 2004).
Thus, our finding that DE-torsinA is a hypoactive torsinAisoform is consistent with the hypothesis thatDE-torsinA
expression in DYT1 dystonia further reduces torsinA ac-
tivity via a dominant-negative mechanism. However, our
experiments do not specifically address this issue.
Previously described animal models of DYT1 dystonia
have been mostly limited to transgenic overexpression
of DE-torsinA (Cao et al., 2005; Koh et al., 2004; Sharma
et al., 2005; Shashidharan et al., 2005; Dang et al., 2005).
While overexpressing DE-torsinA on a wild-type back-
ground has led to varying behavioral and cellular effects,
none of these studies addressed the effect of the DYT1
mutation on normal torsinA function or assessed nu-
clear envelope ultrastructure. Although it is possible to
model a dominant effect in a transgenic study, it is not
generally possible to distinguish between a dominant
gain or loss of function in these experiments. In addition,
the other aspects of the Dgag mutation described
here (e.g., decreased total levels of torsinA protein) are
not modeled by transgenic DE-torsinA expression. To
date, all transgenic animals have been viable, unlike
Tor1aDgag/2 and Tor1aDgag/Dgag mice, and the nuclear
membrane abnormalities seen here have not been re-
ported. Our data also indicate a developmental require-
ment for torsinA function, so differences between trans-
genic and gene-targeted models might relate to the
developmental timing of transgene expression.
The multiple mechanisms by which the DYT1 mutation
can decrease torsinA function, including the potential
for a dominant-negative mechanism, raise the question
of why nuclear envelope vesicles do not develop in
Neuronal Nuclear Membrane Disruption in Tor1a Mice
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(A and C) Spinal cord cryosections from E18 Tor1a+/+ and Tor1a2/2 animals labeled with anti-laminB, NeuroTrace 500/525, and DAPI. Images
show typical appearance of (A) large ventral horn neurons and (C) dorsal horn neurons. Note that the anti-laminB antibody cross reacts with
an extracellular protein and additionally labels areas of the extracellular matrix. Scale bars, 2 mm.
(B and D) Typical nuclear ultrastructure in the (B) ventral and (D) dorsal horns of E18 spinal cord. Scale bars, 2 mm.Tor1aDgag/+ mice. One possibility is that these morpho-
logical abnormalities only develop in the complete ab-
sence of torsinA activity and are therefore not a sensitive
measure of torsinA function. This notion is supported by
the finding that nuclear envelope vesicles do not occur
in heterozygous null mice, which havew50% of normal
torsinA levels. Complete loss of torsinA activity is un-
likely in Tor1aDgag/+ mice (or DYT1 patients) because of
the presence of wild-type torsinA. Unfortunately, it will
not be possible to definitively determine whether DE-
torsinA exerts a dominant-negative effect until the nor-
mal cellular activity of torsinA can be quantitatively
assessed.
The notion that there is a relatively mild biological dis-
turbance in DYT1 dystonia is consistent with clinical fea-
tures of the disease. The DYT1 mutation is roughly 30%
penetrant (w70% of Dgag carriers do not develop dys-tonia), and the majority of patients who do develop dys-
tonic symptoms exhibit relatively localized symptoms.
In fact, only about 10% of Dgag carriers develop debili-
tating dystonia. These observations suggest that DYT1
patients or heterozygous knockin mice are likely to ex-
hibit a rather subtle cellular disturbance. Independent
of the severity of the cellular abnormality underlying
DYT1 dystonia, the fact that the multiple effects of the
Dgag mutation likely combine to impair torsinA activity
argues that the normal cellular action of torsinA is re-
duced in DYT1 dystonia.
Our observations indicate that the nuclear envelope is
a key site of torsinA activity, raising the possibility that
this organelle may be preferentially disrupted in DYT1
patients. Two features of the nuclear membrane pheno-
type described here are consistent with the notion that
nuclear envelope dysfunction contributes to the
Neuron
930Figure 7. Tor1a-Associated Nuclear Enve-
lope Abnormalities Are Absent from Migrat-
ing Neurons
(A) Nuclear envelope abnormalities are ab-
sent from migrating neurons in Tor1a2/2
E12 dorsal cervical spinal cord. Right panel
shows enlargement of boxed area in left
panel. Scale bars, 1 mm.
(B) Vesicles are present in the nuclear enve-
lope lumen of postmigratory E12 ventral spi-
nal cord neurons. Scale bar, 1 mm.
(C) Normal developmental changes in neuro-
nal nuclear morphology. Left panel shows nu-
clei of migrating spinal cord neurons, middle
shows postmigratory maturing neurons and
right panel shows neurons of postnatal day
(P) 14 spinal cord. Scale bars, 10 mm.
(D) Developmental expression of torsinA and
torsinA-interacting proteins LAP1 and LULL1.
25 mg of 1% SDS extracted whole-tissue pro-
tein from wild-type mouse spinal cord or
adult mouse liver.
(E) TorsinA, LAP1, and LULL1 expression in
1% SDS extracted E18 Tor1a+/+ and Tor1a2/2
spinal cord lysates.symptoms of DYT1 dystonia. First, the symptoms of the
disease and the nuclear membrane vesicles are both ex-
clusively neuronal, despite the widespread expression
of torsinA. Second, the onset of disease symptoms
and the appearance of nuclear envelope vesicles both
exhibit a developmental dependence. Thus, we hypoth-
esize that a more moderate insult to the biological path-
way responsible for nuclear membrane vesicle forma-
tion may contribute to the symptoms of DYT1 dystonia.
The nuclear envelope and endoplasmic reticulum
form a continuous membrane system. Nuclear pores
and lamin binding transmembrane proteins are specifi-
cally found in the nuclear envelope, but other functions
and proteins occur in both areas. The membrane abnor-
malities caused by torsinA deficiency appear to be spe-
cifically located in the nuclear envelope lumen, and the
peripheral endoplasmic reticulum generally appears
normal. However, it is possible that torsinA mutation dis-
rupts a process common to the endoplasmic reticulum
and nuclear envelope.
The possibility that a specialized aspect of neuronal
development requires proteins of the nuclear envelope
has not been previously considered. We find that nu-
clear envelope vesicles develop coincident with postmi-
gratory transformation of neuronal nuclear morphology,
raising the possibility that torsinA normally participatesin this poorly understood process. Consistent with this
notion, a number of AAA+ proteins are involved in mem-
brane-localized events such as membrane fusion (Neu-
wald et al., 1999; Ogura and Wilkinson, 2001; Patel and
Latterich, 1998; Vale, 2000). Furthermore, torsinA inter-
acts with the luminal domain of the integral inner nuclear
membrane protein LAP1 (Goodchild and Dauer, 2005),
whose structural features and links to nuclear lamins
(Martin et al., 1995) are consistent with a potential role
in this process. It is also possible that torsinA is involved
in nucleokinesis, a key component of neuronal migra-
tion, in which coupling of the nucleus, centrosome, and
microtubules are used to generate nuclear movement
(Tsai and Gleeson, 2005). Interestingly, a C. elegans
torsinA homolog, ooc-5, is important for the related pro-
cess of nuclear rotation in early stages of embryo devel-
opment (Basham and Rose, 1999). While neuronal mi-
gration appears normal in the torsinA mutants, torsinA
may be involved in disassembly of the nucleokinesis
machinery, the uncoordinated dismantling of which
could lead to abnormal shear forces.
Taken together, our data highlight that the nuclear
envelope undergoes a dynamic reorganization during
neuronal maturation and suggest that alterations in
this process may underlie human neurodevelopmental
disease.
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Nuclear envelope abnormalities in dorsal (A–D) and ventral (E–H) Tor1a2/2 cervical spinal cord at E15 and E18. (A) and (C) show representative
dorsal spinal cord neurons, and (E) and (G) show ventral spinal cord neurons. N, nucleus. Scale bars, 1 mm. Bar graphs shown in (B), (D), (F), and
(H) show the percentage of neurons containing 0, 1 to 9, or 10+ vesicles in the nuclear envelope lumen at either E15 (B and F) or E18 (D and H).
Nuclei of 60 to 100 cells in the dorsal or ventral spinal cord were assessed, and bars show the mean and standard error of measurements from
three separate animals.Experimental Procedures
Characterization of Tor1a Mutant Mice
All Tor1a mutant embryos were delivered by caesarian section from
timed pregnant female mice housed on a standard light-dark cycle.
The day following overnight mating was designated as embryonic
day 0 (E0). Routine histological evaluation was performed on sec-
tions of formaldehyde-fixed embryos stained with haematoxylin and
eosin. Embryos were prepared for immunohistochemistry by trans-
cardial perfusion with 4% formaldehyde. Tissue was cryoprotected
using 30% sucrose, frozen, and 20 mm sections stored at –80ºC until
required. For immunolabeling visualized using peroxidase and 3, 30-
diaminobenzidine (DAB), sections were post-fixed for 10 min, incu-
bated in 0.3% H2O2, incubated with the avidin-biotin kit (Vector
Labs), and permeabilized using 0.25% Triton X-100 in PBS, including
10% normal donkey serum. Primary antibody incubation was per-
formed overnight at 4ºC in permeabilization solution. The following
day, sections were washed in PBS, incubated for 1 hr in biotinylated
secondary antibody (Jackson ImmunoResearch), washed, incu-
bated in ABC reagent (Vector Labs), and developed using DAB sub-
strate (Vector Labs). Immunofluorescent labeling was performed
similarly, except that sections were immediately permeabilized
and blocked following fixation. Primary antibody incubations were
performed at 4ºC overnight, then sections were washed and incu-
bated with Cy3-conjugated secondary antibodies (Jackson Immu-
noResearch). Sections were subsequently washed, incubated with
NeuroTrace 500/525 green fluorescent Nissl stain (Invitrogen/Mo-
lecular Probes) according to the manufacturer’s instructions, and
coverslip mounted using Vectashield with DAPI (Vector Laborato-
ries). Images were obtained using a LSM510 multiphoton micro-
scope (Zeiss). All animal experiments were performed in accordance
with National Health Guidelines for the use of live animals, and the
animal protocol was approved by the Institutional Animal Care and
Use Committee of Columbia University.
Western and Northern Blotting
Protein lysates were produced by sonicating tissues in 100 mM Tris-
HCl buffer (pH 8.0) containing 1% SDS, 150 mM NaCl, and complete
protease inhibitor cocktail (Sigma). Protein concentration was deter-
mined using BCA assay (Pierce). Lysates were diluted in Laemmlisample buffer and used in SDS-PAGE. Total RNA was extracted
from tissue using Trizol Reagent (Invitrogen) according to the man-
ufacturer’s instructions. Northern blots were hybridized using Ex-
pressHyb solution (Clontech) and 32P-labeled DNA probes. Full-
length coding cDNA sequences for mouse torsinA were used as
templates in random priming reactions using Random Priming Kit
(Roche).
Cell Culture
Mouse embryonic fibroblasts (MEF) were prepared after removing
the head and liver from E13 embryos. Tissue was disrupted by three
passages through an 18 gauge needle, and cells were plated in
DMEM containing 15% fetal bovine serum (FBS). Astrocytes were
prepared from E18 frontal cortex that was minced, incubated in
0.25% trypsin for 15 min and dissociated by passaging through
fire-polished glass pipettes of decreasing diameter. Cells were
plated and grown in MEM media containing 10% FBS.
Antibodies
Rabbit anti-torsinA was a kind gift from Brett Lauring (Columbia Uni-
versity). Rabbit polyclonal antibodies against mouse LAP1 and
LULL1 have been described previously (Goodchild and Dauer,
2005). Monoclonal anti-dopamine transporter and rabbit anti-synap-
sin were from Chemicon. Mouse monoclonal anti-myc was from
Clontech, b-actin from Sigma, and anti-GAPH was from Ambion.
Goat polyclonal anti-laminB was from Santa-Cruz.
Ultrastructural Analysis
Tissue was prepared by transcardial perfusion of embryos with 4%
paraformaldehyde/3% glutaraldehyde in 100 mM sodium phos-
phate buffer (pH 7.4), followed by postfixation in the same solution.
Cultured fibroblasts and astrocytes were also fixed in this solution,
then scraped from the dish with a Teflon scrapper and pelleted be-
fore dicing into small pieces. All samples were postfixed with 1% os-
mium tetroxide in 0.1 M cacodylate buffer (pH 7.4) on ice for 1 hr.
Samples were then treated with 0.5% aqueous uranyl acetate, dehy-
drated in graded alcohol, treated with propylene oxide, and embed-
ded in Embed 812 (Electron Microscopy Sciences, Fort Washington,
PA) The resin was polymerized in a 60 degree oven for 2–3 days.
Sections were cut with a Dupont diamond knife on Reichert-Jung
Neuron
932UltraCut E ultramicrotome, collected on copper grids, and doubly
stained with saturated aqueous uranyl acetate and lead citrate. Ul-
trathin sections were viewed using a JEM-1200EX electron micro-
scope manufactured by JEOL, Inc.
Supplemental Data
A detailed description of molecular biology methods used to gener-
ate Tor1a targeted mice is provided in the Supplemental Material
and Supplemental Figure S1 at http://www.neuron.org/cgi/content/
full/48/6/923/DC1/.
Acknowledgments
We are grateful for the work performed by Li Zhang, Meredith Knea-
vel, and John Roseman; and thank Brian McCabe, Lauren Tanabe,
and Hynick Wichterle for their helpful comments regarding the man-
uscript. We also thank Jamie Twaite, Lin Yang, Hong Yi, and Helen
Shio for superb technical work. We thank Rene´ Hen for his advice
and strong support. This work was funded by the Dystonia Medical
Research Foundation, the Bachmann Strauss Foundation, the Par-
kinson’s Disease Foundation, March of Dimes Birth Defects Foun-
dation, NIH R01 HD045708-01A1.
Received: July 19, 2005
Revised: September 30, 2005
Accepted: November 2, 2005
Published: December 21, 2005
References
Altman, J., and Bayer, S.A. (2001). Development of the Human Spinal
Cord (New York: Oxford University Press).
Bandmann, O., and Wood, N.W. (2002). Dopa-responsive dystonia—
the story so far. Neuropediatrics 33, 1–5.
Basham, S.E., and Rose, L.S. (1999). Mutations in ooc-5 and ooc-3
disrupt oocyte formation and the reestablishment of asymmetric
PAR protein localization in two-cell Caenorhabditis elegans em-
bryos. Dev. Biol. 215, 253–263.
Berardelli, A., Rothwell, J.C., Hallett, M., Thompson, P.D., Manfredi,
M., and Marsden, C.D. (1998). The pathophysiology of primary dys-
tonia. Brain 121, 1195–1212.
Bressman, S.B., de Leon, D., Kramer, P.L., Ozelius, L.J., Brin, M.F.,
Greene, P.E., Fahn, S., Breakefield, X.O., and Risch, N.J. (1994). Dys-
tonia in Ashkenazi Jews: clinical characterization of a founder muta-
tion. Ann. Neurol. 36, 771–777.
Cao, S., Gelwix, C.C., Caldwell, K.A., and Caldwell, G.A. (2005). Tor-
sin-mediated protection from cellular stress in the dopaminergic
neurons of Caenorhabditis elegans. J. Neurosci. 25, 3801–3812.
Dang, M.T., Yokoi, F., McNaught, K.S., Jengelley, T.A., Jackson, T.,
Li, J., and Li, Y. (2005). Generation and characterization of Dyt1
DeltaGAG knock-in mouse as a model for early-onset dystonia.
Exp. Neurol. 196, 452–463.
Fahn, S., Marsden, C.D., and Calne, D.B. (1987). Classification and
investigation of dystonia. In Movement Disorders 2, C.D. Marsden,
and S. Fahn, eds. (London: Butterworths), pp. 332–358.
Gerace, L. (2004). TorsinA and torsion dystonia: Unraveling the ar-
chitecture of the nuclear envelope. Proc. Natl. Acad. Sci. USA 101,
8839–8840.
Gonzalez-Alegre, P., and Paulson, H.L. (2004). Aberrant cellular be-
havior of mutant torsinA implicates nuclear envelope dysfunction in
DYT1 dystonia. J. Neurosci. 24, 2593–2601.
Goodchild, R.E., and Dauer, W.T. (2004). Mislocalization to the nu-
clear envelope: An effect of the dystonia causing torsinA mutation.
Proc. Natl. Acad. Sci. USA 101, 847–852.
Goodchild, R.E., and Dauer, W.T. (2005). The AAA+ protein torsinA
interacts with a conserved domain present in LAP1 and a novel ER
protein. J. Cell Biol. 168, 855–862.
Koh, Y.H., Rehfeld, K., and Ganetzky, B. (2004). A Drosophila model
of early onset torsion dystonia suggests impairment in TGF-beta
signaling. Hum. Mol. Genet. 13, 2019–2030.Kustedjo, K., Bracey, M.H., and Cravatt, B.F. (2000). Torsin A and its
torsion dystonia-associated mutant forms are lumenal glycopro-
teins that exhibit distinct subcellular localizations. J. Biol. Chem.
275, 27933–27939.
Liu, Z., Zolkiewska, A., and Zolkiewski, M. (2003). Characterization of
human torsinA and its dystonia-associated mutant form. Biochem.
J. 374, 117–122.
Martin, L., Crimaudo, C., and Gerace, L. (1995). cDNA cloning and
characterization of lamina-associated polypeptide 1C (LAP1C), an
integral protein of the inner nuclear membrane. J. Biol. Chem. 270,
8822–8828.
Naismith, T.V., Heuser, J.E., Breakefield, X.O., and Hanson, P.I.
(2004). TorsinA in the nuclear envelope. Proc. Natl. Acad. Sci. USA
101, 7612–7617.
Neuwald, A.F., Aravind, L., Spouge, J.L., and Koonin, E.V. (1999).
AAA+: A class of chaperone-like ATPases associated with the as-
sembly, operation, and disassembly of protein complexes. Genome
Res. 9, 27–43.
Ogura, T., and Wilkinson, A.J. (2001). AAA+ superfamily ATPases:
common structure–diverse function. Genes Cells 6, 575–597.
Ozelius, L.J., Hewett, J.W., Page, C.E., Bressman, S.B., Kramer,
P.L., Shalish, C., de Leon, D., Brin, M.F., Raymond, D., Corey,
D.P., et al. (1997). The early-onset torsion dystonia gene (DYT1) en-
codes an ATP-binding protein. Nat. Genet. 17, 40–48.
Patel, S., and Latterich, M. (1998). The AAA team: related ATPases
with diverse functions. Trends Cell Biol. 8, 65–71.
Peters, A., Palay, S.L., and Webster, H.deF. (1991). The Fine Struc-
ture of the Nervous System: Neurons and Their Supporting Cells
(New York: Oxford University Press).
Rakic, P., Stensas, L.J., Sayre, E., and Sidman, R.L. (1974). Com-
puter-aided three-dimensional reconstruction and quantitative anal-
ysis of cells from serial electron microscopic montages of foetal
monkey brain. Nature 250, 31–34.
Sharma, N., Baxter, M.G., Petravicz, J., Bragg, D.C., Schienda, A.,
Standaert, D.G., and Breakefield, X.O. (2005). Impaired motor learn-
ing in mice expressing torsinA with the DYT1 dystonia mutation.
J. Neurosci. 25, 5351–5355.
Shashidharan, P., Sandu, D., Potla, U., Armata, I.A., Walker, R.H.,
McNaught, K.S., Weisz, D., Sreenath, T., Brin, M.F., and Olanow,
C.W. (2005). Transgenic mouse model of early-onset DYT1 dystonia.
Hum. Mol. Genet. 14, 125–133.
Torres, G.E., Sweeney, A.L., Beaulieu, J.M., Shashidharan, P., and
Caron, M.G. (2004). Effect of torsinA on membrane proteins reveals
a loss of function and a dominant-negative phenotype of the dysto-
nia-associated DeltaE-torsinA mutant. Proc. Natl. Acad. Sci. USA
101, 15650–15655.
Tsai, L.H., and Gleeson, J.G. (2005). Nucleokinesis in neuronal mi-
gration. Neuron 46, 383–388.
Vale, R.D. (2000). AAA proteins. Lords of the ring. J. Cell Biol. 150,
F13–F19.
Note Added in Proof
Since acceptance of this manuscript, Dang et al. have published
a behavioral characterization of adult heterozygote Tor1aDgag/+
animals.
